Skip to main content
VivoSim Labs, INC. logo

VivoSim Labs, INC. — Investor Relations & Filings

Ticker · VIVS ISIN · US68620A2033 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2016-07-14 Director's Dealing
Country US United States of America
Listing US VIVS

About VivoSim Labs, INC.

https://organovo.com/

VivoSim Labs, Inc. is a biotechnology services company that develops and utilizes bioprinted, three-dimensional (3D) human tissues designed to emulate human biology and disease. The company provides testing services for drugs and drug candidates, primarily for the pharmaceutical and biotechnology sectors. VivoSim Labs specializes in offering liver and intestinal toxicology insights through its proprietary New Approach Methodologies (NAMs), including its NAMkind™ 3D models. These non-animal testing platforms are used to generate human-relevant safety and toxicology data early in the drug discovery and development process, aiming to provide insights before animal studies or clinical trials.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2016-07-14 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filing with the SEC, dated July 5, 2016, from Organovo Holdings, Inc. The content focuses on the departure of a board member, Richard Heyman, Ph.D., including his retirement and the company's search for a replacement. This corresponds to an announcement of changes in the company's board of directors. The document is not a full report but a regulatory announcement about management changes, fitting the Board/Management Information category (MANG). The document length is short (3011 characters), consistent with a typical 8-K announcement of management changes rather than a detailed report.
2016-07-08 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes details about the Annual Meeting, proposals to be voted on, director nominations, appointment of auditors, advisory votes on executive compensation, and approval of an employee stock purchase plan. The presence of voting proposals and the nature of the document as a solicitation for shareholder votes clearly identifies it as Proxy Solicitation & Information Statement material. The document length is under 5,000 characters but contains substantive proxy information, not just an announcement or a link to a report, so it is not a Report Publication Announcement. Therefore, the correct classification is PSI.
2016-07-08 English
DEF 14A
Proxy Solicitation & Information Statement
2016-07-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 9, 2016, by Organovo Holdings, Inc. It specifically states in Item 2.02 that the company issued a press release announcing financial results for the fourth quarter and fiscal year ended March 31, 2016. The document includes the press release as Exhibit 99.1. The text clarifies that this is a current report furnishing financial results information, not the full financial report itself. The document length is 2844 characters, which is relatively short and consistent with an 8-K filing announcing earnings results rather than the full earnings report. According to the classification rules, an 8-K filing announcing earnings results corresponds to an Earnings Release (ER) filing type, as it is the initial announcement of quarterly/periodical financial results with key highlights only. Therefore, the correct classification is ER with high confidence.
2016-06-09 English
10-K
Annual Report FY 2016
2016-06-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.